Since this drug-specific side effect had already been recognised during pre-marketing phase II–III studies and continues to be non-reported in any anti-IL-13 treated cohort, it is highly likely that conjunctivitis will not be associated with long-term IL-13 elimination. The gene discussed is IL13; the disease is conjunctivitis.